Coca-Cola Europacific Partners plc has announced a significant share buyback program. The company confirmed that it purchased 200,000 ordinary shares between November 2 and November 6, 2026. This strategic move is aimed at enhancing shareholder value and reflects the company's ongoing commitment to its investors.
The share buyback program comes as part of a broader initiative announced earlier this year, where Coca-Cola Europacific Partners plans to repurchase up to EUR 1 billion of its ordinary shares. The shares acquired during this period will be cancelled, effectively reducing the total number of shares outstanding.
Background
Coca-Cola Europacific Partners plc is a leading consumer goods company in the bottled and canned soft drinks and carbonated waters sector, classified under SIC 2086. The company operates under the ticker symbol CCEP on the Nasdaq exchange and is recognized for its extensive portfolio of beverages, serving nearly 600 million consumers across 31 countries.
Recent filings indicate that the company has been active in the market, with multiple reports submitted in November 2026 alone. This includes the current filing, which highlights the company's ongoing efforts to manage its share structure effectively.
What the Filing Says
The recent filing states, "The Company confirms that from 2 November 2026 up to and including 6 November 2026 it purchased a total of: (i) 150,000 ordinary shares of EUR 0.01 on the US Trading Venues and (ii) 50,000 ordinary shares on the London Trading Venues." This confirms the company's active participation in the share buyback program.
Impact
This buyback initiative may positively impact shareholders by potentially increasing the value of remaining shares. As Coca-Cola Europacific Partners continues to repurchase its stock, it may also influence the broader bottled and canned soft drinks industry, prompting competitors to consider similar strategies to enhance shareholder returns.
What's Next
The filing does not specify what happens next, but the ongoing buyback program is expected to continue as planned, with further updates likely to follow in future filings.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










